Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

CSFB Lowers Myogen to Neutral

Credit Suisse First Boston downgraded Myogen (MYOG) to neutral.

Analyst Mark Augustine says he's downgrading after the company reported disappointing results from Emote, a Phase III study of its oral enoximone. Along with the downgrade, he cut the price target to $17 by "probability-adjusting" downward the value of the enoximone program.

Augustine notes the study was designed to evaluate whether enoximone capsules could effectively wean patients with chronic heart failure off of i.v. intrope therapy He had expected the study to succeed in meeting its primary endpoint. Augustine maintains the $2.51 2004 loss per share estimate.

blog comments powered by Disqus